Adriano R Tonelli1, Diego Conci2, Balaji K Tamarappoo3, Jennie Newman2, Raed A Dweik2. 1. Department of Pulmonary, Allergy and Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address: tonella@ccf.org. 2. Department of Pulmonary, Allergy and Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, Ohio. 3. Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
Abstract
BACKGROUND: It is unknown whether the echocardiographic changes observed after treatment of patients with pulmonary arterial hypertension have prognostic value. METHODS: Subjects with pulmonary arterial hypertension, confirmed by right heart catheterization, who underwent Doppler echocardiography before (baseline) and after 1 year of treatment (follow-up) with parenteral prostacyclin analogues were retrospectively identified. Echocardiographic parameters were measured offline by two investigators. RESULTS: A total of 48 patients were included (mean age, 45 ± 14 years; 83% women). Compared with baseline, follow-up echocardiography showed reductions in right atrial area (mean percentage change, 12 ± 25%; P < .001), right ventricular (RV) basal and middle cavity dimensions (mean percentage change, 8.5 ± 14% [P < .001] and 6.8 ± 17% [P = .005], respectively), and peak tricuspid regurgitant velocity (mean percentage change, 10 ± 14%; P < .001). Tricuspid annular plane systolic excursion (mean percentage change, 36 ± 43%; P < .001) and RV outflow tract time-velocity integral (mean percentage change, 48 ± 66%; P < .001) increased. During a median follow-up period of 52.5 months (interquartile range, 20.5-80 months), 18 patients (37.5%) died, mostly (n = 15 [83%]) from progression of pulmonary arterial hypertension. The changes in RV end-diastolic area (hazard ratio [HR per 10% decrease, 0.73; 95% confidence interval [CI], 0.57-0.93), tricuspid valve regurgitation velocity (HR per 10 cm/sec decrease, 0.58; 95% CI, 0.37-0.89), RV outflow tract velocity-time integral (HR per 10% increase, 0.90; 95% CI, 0.83-0.98), and subjective RV function (HR per 1 unit of improvement [e.g., from moderate to mild], 0.55; 95% CI, 0.31-0.96) were associated with overall mortality. CONCLUSIONS: Echocardiographic parameters that estimate RV systolic pressure and assess RV morphology and function improve after 1 year of prostacyclin analogue treatment, and the degree of change has prognostic implications.
BACKGROUND: It is unknown whether the echocardiographic changes observed after treatment of patients with pulmonary arterial hypertension have prognostic value. METHODS: Subjects with pulmonary arterial hypertension, confirmed by right heart catheterization, who underwent Doppler echocardiography before (baseline) and after 1 year of treatment (follow-up) with parenteral prostacyclin analogues were retrospectively identified. Echocardiographic parameters were measured offline by two investigators. RESULTS: A total of 48 patients were included (mean age, 45 ± 14 years; 83% women). Compared with baseline, follow-up echocardiography showed reductions in right atrial area (mean percentage change, 12 ± 25%; P < .001), right ventricular (RV) basal and middle cavity dimensions (mean percentage change, 8.5 ± 14% [P < .001] and 6.8 ± 17% [P = .005], respectively), and peak tricuspid regurgitant velocity (mean percentage change, 10 ± 14%; P < .001). Tricuspid annular plane systolic excursion (mean percentage change, 36 ± 43%; P < .001) and RV outflow tract time-velocity integral (mean percentage change, 48 ± 66%; P < .001) increased. During a median follow-up period of 52.5 months (interquartile range, 20.5-80 months), 18 patients (37.5%) died, mostly (n = 15 [83%]) from progression of pulmonary arterial hypertension. The changes in RV end-diastolic area (hazard ratio [HR per 10% decrease, 0.73; 95% confidence interval [CI], 0.57-0.93), tricuspid valve regurgitation velocity (HR per 10 cm/sec decrease, 0.58; 95% CI, 0.37-0.89), RV outflow tract velocity-time integral (HR per 10% increase, 0.90; 95% CI, 0.83-0.98), and subjective RV function (HR per 1 unit of improvement [e.g., from moderate to mild], 0.55; 95% CI, 0.31-0.96) were associated with overall mortality. CONCLUSIONS: Echocardiographic parameters that estimate RV systolic pressure and assess RV morphology and function improve after 1 year of prostacyclin analogue treatment, and the degree of change has prognostic implications.
Authors: William A Zoghbi; Maurice Enriquez-Sarano; Elyse Foster; Paul A Grayburn; Carol D Kraft; Robert A Levine; Petros Nihoyannopoulos; Catherine M Otto; Miguel A Quinones; Harry Rakowski; William J Stewart; Alan Waggoner; Neil J Weissman Journal: J Am Soc Echocardiogr Date: 2003-07 Impact factor: 5.251
Authors: Allan L Klein; Suhny Abbara; Deborah A Agler; Christopher P Appleton; Craig R Asher; Brian Hoit; Judy Hung; Mario J Garcia; Itzhak Kronzon; Jae K Oh; E Rene Rodriguez; Hartzell V Schaff; Paul Schoenhagen; Carmela D Tan; Richard D White Journal: J Am Soc Echocardiogr Date: 2013-09 Impact factor: 5.251
Authors: Miguel Bustamante-Labarta; Sergio Perrone; Ricardo Leon De La Fuente; Pablo Stutzbach; Ricardo Perez De La Hoz; Augusto Torino; Roberto Favaloro Journal: J Am Soc Echocardiogr Date: 2002-10 Impact factor: 5.251
Authors: D B Badesch; V F Tapson; M D McGoon; B H Brundage; L J Rubin; F M Wigley; S Rich; R J Barst; P S Barrett; K M Kral; M M Jöbsis; J E Loyd; S Murali; A Frost; R Girgis; R C Bourge; D D Ralph; C G Elliott; N S Hill; D Langleben; R J Schilz; V V McLaughlin; I M Robbins; B M Groves; S Shapiro; T A Medsger Journal: Ann Intern Med Date: 2000-03-21 Impact factor: 25.391
Authors: Nazzareno Galiè; Alan L Hinderliter; Adam Torbicki; Thierry Fourme; Gerald Simonneau; Tomas Pulido; Nilda Espinola-Zavaleta; Guido Rocchi; Alessandra Manes; Robert Frantz; Marcin Kurzyna; Sherif F Nagueh; Robyn Barst; Richard Channick; Karl Dujardin; Andrew Kronenberg; Isabelle Leconte; Maurizio Rainisio; Lewis Rubin Journal: J Am Coll Cardiol Date: 2003-04-16 Impact factor: 24.094
Authors: Ronald J Raymond; Alan L Hinderliter; Park W Willis; David Ralph; Edgar J Caldwell; William Williams; Neil A Ettinger; Nicholas S Hill; Warren R Summer; Bennett de Boisblanc; Todd Schwartz; Gary Koch; Linda M Clayton; Maria M Jöbsis; James W Crow; Walker Long Journal: J Am Coll Cardiol Date: 2002-04-03 Impact factor: 24.094
Authors: Gerald Simonneau; Robyn J Barst; Nazzareno Galie; Robert Naeije; Stuart Rich; Robert C Bourge; Anne Keogh; Ronald Oudiz; Adaani Frost; Shelmer D Blackburn; James W Crow; Lewis J Rubin Journal: Am J Respir Crit Care Med Date: 2002-03-15 Impact factor: 21.405
Authors: Roald J Roeleveld; Anton Vonk-Noordegraaf; J Tim Marcus; Jean G F Bronzwaer; Koen M J Marques; Pieter E Postmus; Anco Boonstra Journal: Chest Date: 2004-02 Impact factor: 9.410
Authors: Martin Koestenberger; Mark K Friedberg; Eirik Nestaas; Ina Michel-Behnke; Georg Hansmann Journal: Pulm Circ Date: 2016-03 Impact factor: 3.017
Authors: Ketul R Chaudhary; Yupu Deng; Colin M Suen; Mohamad Taha; Thomas H Petersen; Shirley H J Mei; Duncan J Stewart Journal: Br J Pharmacol Date: 2018-09-16 Impact factor: 8.739
Authors: Martin Koestenberger; Bert Nage; William Ravekes; Alexander Avian; Ante Burmas; Gernot Grangl; Gerhard Cvirn; Andreas Gamillscheg Journal: Pediatr Cardiol Date: 2015-03-06 Impact factor: 1.655
Authors: Martin Koestenberger; Ante Burmas; William Ravekes; Alexander Avian; Andreas Gamillscheg; Gernot Grangl; Marlene Grillitsch; Georg Hansmann Journal: Pediatr Cardiol Date: 2015-12-26 Impact factor: 1.655
Authors: V J M Baggen; M M P Driessen; M C Post; A P van Dijk; J W Roos-Hesselink; A E van den Bosch; J J M Takkenberg; G T Sieswerda Journal: Neth Heart J Date: 2016-06 Impact factor: 2.380
Authors: Vivan J M Baggen; Tim Leiner; Marco C Post; Arie P van Dijk; Jolien W Roos-Hesselink; Eric Boersma; Jesse Habets; Gertjan Tj Sieswerda Journal: Eur Radiol Date: 2016-02-04 Impact factor: 5.315